MA
AKBA icon

MUFG Americas’s Akebia Therapeutics AKBA Stock Holding History

MUFG Americas’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-204
Closed -$3K – 859
2017
Q4 		$3K Sell
204
-124
-38% -$2.06K ﹤0.01% 922
2017
Q3 		$6K Buy
+328
New +$5.04K ﹤0.01% 917
2016
Q2 		– Sell
-480
Closed -$4K – 1097
2016
Q1 		$4K Sell
480
-330
-41% -$2.68K ﹤0.01% 978
2015
Q4 		$10K Hold
810
– – ﹤0.01% 830
2015
Q3 		$8K Buy
810
+60
+8% +$551 ﹤0.01% 898
2015
Q2 		$8K Hold
750
– – ﹤0.01% 892
2015
Q1 		$8K Buy
750
+160
+27% +$1.7K ﹤0.01% 951
2014
Q4 		$7K Buy
+590
New +$8.46K ﹤0.01% 1022

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

MUFG Americas's AKBA Position: Q1 2018 in Review

MUFG Americas sold out of Akebia Therapeutics (AKBA) in Q1 2018, closing a stake of 204 shares — an estimated $3K sold.

MUFG Americas first reported a position in AKBA in Q4 2014 and held it in 8 quarters. The position peaked at $10K in Q4 2015. 153 funds tracked by Wall St. Rank hold AKBA as of Q1 2018.

  • MUFG Americas reported no remaining Akebia Therapeutics position as of Q1 2018 after selling out during the quarter.
  • MUFG Americas sold 204 Akebia Therapeutics shares in Q1 2018, an estimated $3K.
  • MUFG Americas first reported a position in Akebia Therapeutics in Q4 2014 and held it in 8 quarters.
  • MUFG Americas's Akebia Therapeutics position peaked at $10K in Q4 2015.
  • 153 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2018.

Based on MUFG Americas's 13F filing for Q1 2018, filed 7 May 2018.